Market revenue in 2023 | USD 2,183.7 million |
Market revenue in 2030 | USD 24,546.9 million |
Growth rate | 41.3% (CAGR from 2023 to 2030) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | |
Key market players worldwide | Novo Nordisk A/S ADR, GlaxoSmithKline, Novartis AG ADR, Icahn Enterprises LP Depositary Units Repr Units of LP Interests, Rhythm Pharmaceuticals Inc, PureTech Health PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-obesity medication market will help companies and investors design strategic landscapes.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe anti-obesity medication market , including forecasts for subscribers. This continent databook contains high-level insights into Europe anti-obesity medication market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account